Natera Inc (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 3,192 shares of Natera stock in a transaction on Monday, March 11th. The stock was sold at an average price of $16.00, for a total transaction of $51,072.00. Following the sale, the chief financial officer now directly owns 13,422 shares in the company, valued at approximately $214,752. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Michael Burkes Brophy also recently made the following trade(s):

  • On Monday, December 24th, Michael Burkes Brophy sold 449 shares of Natera stock. The stock was sold at an average price of $12.39, for a total value of $5,563.11.

Shares of NASDAQ NTRA traded up $0.22 during trading on Friday, hitting $19.14. 18,084 shares of the company were exchanged, compared to its average volume of 610,960. Natera Inc has a 12-month low of $8.60 and a 12-month high of $29.62. The company has a quick ratio of 2.32, a current ratio of 2.44 and a debt-to-equity ratio of 1.30. The firm has a market cap of $1.03 billion, a PE ratio of -9.00 and a beta of 1.84.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Tuesday, March 12th. The medical research company reported ($0.51) EPS for the quarter, hitting the consensus estimate of ($0.51). Natera had a negative return on equity of 1,214.02% and a negative net margin of 49.72%. The business had revenue of $67.00 million for the quarter, compared to analyst estimates of $62.87 million. Research analysts expect that Natera Inc will post -1.59 EPS for the current year.

Several research firms have recently commented on NTRA. BidaskClub lowered Natera from a “sell” rating to a “strong sell” rating in a report on Friday, March 1st. Zacks Investment Research upgraded Natera from a “sell” rating to a “hold” rating in a report on Friday. Finally, Canaccord Genuity reiterated a “buy” rating and set a $25.00 price target on shares of Natera in a report on Monday. One analyst has rated the stock with a sell rating, two have given a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $27.75.

A number of institutional investors and hedge funds have recently modified their holdings of NTRA. Great West Life Assurance Co. Can raised its holdings in Natera by 136.8% in the 4th quarter. Great West Life Assurance Co. Can now owns 5,920 shares of the medical research company’s stock valued at $80,000 after buying an additional 3,420 shares during the period. Legal & General Group Plc raised its holdings in Natera by 14.5% in the 4th quarter. Legal & General Group Plc now owns 5,826 shares of the medical research company’s stock valued at $81,000 after buying an additional 736 shares during the period. Pacer Advisors Inc. purchased a new stake in Natera in the 3rd quarter valued at about $106,000. Point72 Hong Kong Ltd purchased a new stake in Natera in the 3rd quarter valued at about $119,000. Finally, Quantbot Technologies LP purchased a new stake in Natera in the 3rd quarter valued at about $135,000. Hedge funds and other institutional investors own 90.05% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was first published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://theolympiareport.com/2019/03/15/michael-burkes-brophy-sells-3192-shares-of-natera-inc-ntra-stock.html.

Natera Company Profile

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Read More: Understanding Analyst Recommendations

Insider Buying and Selling by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.